Background
Phase 3, open-label, randomized controlled trial (CLL10; German CLL Study Group). N=564 fit treatment-naive CLL patients (CIRS ≤6, creatinine clearance ≥70 mL/min), all candidates for FCR but randomized to FCR vs the less intensive bendamustine-rituximab (BR). Del(17p) patients were excluded. Head-to-head comparison of the two main fit-CLL chemoimmunotherapy regimens. Median age 61 years.
Interventions and follow up
Arm A: FCR: fludarabine 25 mg/m² IV days 1–3 + cyclophosphamide 250 mg/m² IV days 1–3 + rituximab 375 mg/m² day 1 cycle 1 / 500 mg/m² day 1 cycles 2–6; 6 cycles q28d
Arm B: BR: bendamustine 90 mg/m² IV days 1–2 + rituximab 375 mg/m² day 1 cycle 1 / 500 mg/m² day 1 cycles 2–6; 6 cycles q28d
Primary endpoint: Progression-free survival (PFS)
Median follow up: 37.1 months
Arm B: BR: bendamustine 90 mg/m² IV days 1–2 + rituximab 375 mg/m² day 1 cycle 1 / 500 mg/m² day 1 cycles 2–6; 6 cycles q28d
Primary endpoint: Progression-free survival (PFS)
Median follow up: 37.1 months
Results
Median PFS: 55.2 vs 41.7 months (FCR vs BR), HR 0.63 (95% CI 0.48–0.84), P<.001
ORR: 97.8% vs 96.8%
CR: 40.7% vs 31.5% (P=.026)
OS: HR 1.07 (95% CI 0.62–1.84), P=.59 — no significant difference
Grade ≥3 infections: 39.0% (FCR) vs 25.4% (BR)
ORR: 97.8% vs 96.8%
CR: 40.7% vs 31.5% (P=.026)
OS: HR 1.07 (95% CI 0.62–1.84), P=.59 — no significant difference
Grade ≥3 infections: 39.0% (FCR) vs 25.4% (BR)
Adverse events
Hematologic: Grade ≥3 neutropenia 83.7% (FCR) vs 58.5% (BR).
Infections: Grade ≥3 infections 39.0% vs 25.4% — significantly higher with FCR; neutropenic fever more common with FCR.
Other: Infusion reactions comparable between arms.
Secondary malignancy/tolerability: Secondary MDS/AML 1.0% (FCR) vs 0.7% (BR); treatment delay or modification 54% vs 42%.
Infections: Grade ≥3 infections 39.0% vs 25.4% — significantly higher with FCR; neutropenic fever more common with FCR.
Other: Infusion reactions comparable between arms.
Secondary malignancy/tolerability: Secondary MDS/AML 1.0% (FCR) vs 0.7% (BR); treatment delay or modification 54% vs 42%.
Conclusions
FCR showed superior PFS over BR in fit treatment-naive CLL, but with significantly higher hematologic toxicity and infection rates and no OS benefit. BR offers an effective, less toxic alternative, particularly for patients at higher risk for cytopenic or infectious complications despite meeting eligibility for FCR.
Key Limitations
PFS benefit of FCR was not accompanied by an OS benefit and was largely driven by the IGHV-unmutated subgroup, whereas IGHV-mutated patients had similar outcomes with both regimens. Higher grade ≥3 neutropenia and infections with FCR limit its use in patients with frequent infections or impaired marrow reserve. Younger cohort (median 61) — results not applicable to older or unfit patients. Both FCR and BR are now largely supplanted by BTKi- or BCL-2i-based regimens.
Clinical Context
CLL10 confirmed the FCR PFS advantage but highlighted its toxicity trade-off, reinforcing BR as an acceptable alternative especially in older-fit patients. In contemporary practice, both FCR and BR have largely been replaced by BTKi-based (ibrutinib, acalabrutinib, zanubrutinib) or fixed-duration venetoclax-based regimens, which offer superior efficacy and often better tolerability. Chemoimmunotherapy remains relevant for IGHV-mutated younger patients seeking potential functional cure. ESMO-MCBS: not applicable (comparative chemoimmunotherapy).